; and (2) not later than 1 year after the date of enactment of this Act, publish a plan for rapidly expanding public and private diagnostic testing capacity (including at clinical laboratories, at public health department laboratories, and by means of self-testing) in an influenza pandemic, including addressing transportation infrastructure, the need for sterilization, and sourcing critical raw materials, components, and parts. (e) Scaling up prophylactic influenza antibody products that address gaps in coverage The Director of the Biomedical Advanced Research and Development Authority may conduct or support preventive approaches, including those still in preclinical and clinical stages, to rapidly scale up preexposure prophylactic influenza antibody products that address influenza infection. (f) Modernizing potency assays The Commissioner of Food and Drugs shall work with vaccine manufacturers to modernize potency assays across a variety of manufacturing technologies so as to reduce by 6 weeks the period required to first evaluate new vaccine candidates during a pandemic. (g) Improved influenza therapeutics The Director of the Biomedical Advanced Research and Development Authority may conduct or support improved influenza therapeutics that— (1) are more broadly protective